Seamless gene correction of β -
thalassemia mutations in patient - specific iPSCs using CRISPR / Cas9 and piggyBac.
Not exact matches
Then a team of Chinese researchers used that base editor to correct a
mutation in human embryos that causes the blood disorder beta -
thalassemia, reported September 23 in Protein & Cell (SN: 11/25/17, p. 7).
Other plans include using CRISPR to reverse blood disorders, such as sickle cell anemia and beta
thalassemia, caused by
mutations in the hemoglobin gene.
A Yale - led research team used a new gene editing strategy to correct
mutations that cause
thalassemia, a form of anemia.
The team first created embryos with genetic
mutations that caused two different diseases: β -
thalassemia and favism (an anemia caused by eating fava beans).
When they tried correcting the
mutations using CRISPR - Cas9, their success rate was one in four for β -
thalassemia and two in two for favism, they report this month in Molecular Genetics and Genomics.
The A and B blood groups (chromosome 9) protect against cholera; the cystic fibrosis and Tay - Sachs (15)
mutations may protect against tuberculosis; the sickle - cell (11) and
thalassemia (16)
mutations protect against malaria.
For unknown reasons, the ATR - X
mutation causes mild a
thalassemia even though the a globin gene is normal.
Gene editing has emerged as a promising strategy to treat diseases like β -
thalassemia and sickle cell disease which are both caused by
mutations in the gene for β - globin (HBB).
β -
thalassemia is an inherited disorder caused by
mutations in the β - globin chain of haemoglobin that lead to... Continue reading Animal research: At the forefront of modern medicine
In a recent study, Chinese researchers used CRISPR / Cas in human embryos to correct a
mutation that causes the blood disease beta -
thalassemia.
The technique is also inefficient, correcting only a small percentage of gene
mutations, and transplantation success has proven rare in clinical trials testing gene therapy to treat beta
thalassemia.